Short Summary
Biofrontera AG et al. challenged U.S. Patent No. 11,697,028 held by DUSA Pharmaceuticals, Inc., alleging obviousness under 35 U.S.C. § 103. The challenge focuses on the combination of prior art references to demonstrate that specific Photodynamic Therapy (PDT) illuminator claims are unpatentable.
Detailed Summary
This Petition challenges U.S. Patent No. 11,697,028 by Biofrontera AG et al., asserting obviousness over combinations of prior art references under § 103. The Petitioner presents three specific grounds: Ground 1 combines Larsen, Bansal, and Jones against Claims 1, 2, 4-8, 16-21; Ground 2 uses Larsen, Bansal, Jones, and Anderson to show obviousness for optimized PDT conditions (Claims 2-4); and Ground 3 adds Mackinnon's sensor technology to the existing combination for improved targeting (Claims 10, 11, 13, 14).
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Biofrontera AG et al. vs Sun Pharmaceutical Industries, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Ericsson Inc. et al.vsPegasus Wireless Innovation LLC
The PTAB denied institution for an IPR concerning Pegasus Wireless Innovation LLC's patent, citing the proximity and significant investment in related district court proceedings. This decision emphasizes efficiency considerations under Fintiv factors when parallel litigation is active.
Cisco Systems, Inc.vsPortsmouth Network Corporation
The PTAB issued a Final Written Decision finding that claims 1-18 of the patent were unpatentable on grounds of obviousness over Kovvali and Kalman. The Board rejected the Petitioner's arguments, agreeing with the Patent Owner that there was no valid motivation to combine the references for resource allocation in ring topology data flow.
Bruker Spatial Biology, Inc.vs10x Genomics, Inc. et al.
Bruker Spatial Biology and 10x Genomics settled their dispute over U.S. Patent 11,542,554, leading the PTAB to terminate the inter partes review. The settlement agreement and related documents were ordered confidential.
SHENZHEN PINCAN TECHNOLOGY CO., LTDvsThe Ridge Wallet LLC
The Ridge Wallet and Shenzhen Pincan Technology have settled their dispute over U.S. Patent 10,791,808 and filed a joint motion to terminate the inter partes review.
Bruker Spatial Biology, Inc.vs10x Genomics, Inc. et al.
Bruker Spatial Biology, Inc. and 10x Genomics jointly asked the PTAB to file their settlement agreement as business‑confidential information and keep it separate from the patent file. The request invokes 35 U.S.C. § 317 and related regulations to protect the settlement details.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.